5 Most Profitable Drugs In The World

2. Humira

2022 Sales: $21.23 billion 

Due to pandemic demand, Pfizer’s COVID-19 vaccine surpassed AbbVie’s Humira as the top-selling drug. Humira still generated $21.23 billion in global sales but faced competition from biosimilars, leading to a 10% decline in international sales. In the U.S., biosimilar rivals will launch throughout 2023, impacting Humira’s market share.

AbbVie focuses on Skyrizi and Rinvoq to compensate for Humira’s impending patent expiration, aiming for a combined $15 billion in global sales by 2023. AbbVie anticipates a 45% erosion in Humira sales in 2023. The company has faced criticism for patent strategies and price increases. Humira is FDA-approved to treat various diseases.